ACAD
ACADIA Pharmaceuticals Inc.NASDAQHealthcare$22.20-0.54%ClosedMarket Cap: $3.78B
As of 2026-04-06
Valuation
P/E (TTM)
9.68
PEG
0.13
P/B
3.08
P/S
3.55
EV/EBITDA
28.00
DCF Value
$-40.11
FCF Yield
2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.7%
Operating Margin
9.8%
Net Margin
36.5%
ROE
41.9%
ROA
25.0%
ROIC
8.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $284.0M | 90.8% | $17.4M | $273.6M | $1.60 | — |
| FY 2025 | $1.07B | 91.7% | $104.8M | $391.0M | $2.29 | — |
| Q3 2025 | $278.6M | 92.2% | $35.8M | $71.8M | $0.42 | — |
| Q2 2025 | $264.6M | 92.2% | $32.4M | $26.7M | $0.16 | — |
| Q1 2025 | $244.3M | 91.7% | $19.3M | $19.0M | $0.11 | — |
| Q4 2024 | $259.6M | 91.6% | $153.5M | $143.7M | $0.86 | — |
| FY 2024 | $957.8M | 91.5% | $230.8M | $226.5M | $1.36 | — |
| Q3 2024 | $250.4M | 92.5% | $31.6M | $32.8M | $0.20 | — |
| Q2 2024 | $242.0M | 92.5% | $30.4M | $33.4M | $0.20 | — |
| Q1 2024 | $205.8M | 88.8% | $15.2M | $16.6M | $0.10 | — |
| Q4 2023 | $231.0M | 92.3% | $34.9M | $45.8M | $0.28 | — |
| FY 2023 | $726.4M | 93.7% | $-73.4M | $-61.3M | $-0.37 | — |